DiscoveryProbe™ FDA-approved Drug Library: Enabling High-Throughput Drug Repositioning and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) comprises 2,320 clinically approved compounds suitable for high-throughput and high-content screening workflows (ApexBio). All compounds are supplied at 10 mM in DMSO, with validated stability for up to 24 months at -80°C. This library enables drug repositioning by providing access to agents with well-characterized mechanisms, including receptor agonists/antagonists, enzyme inhibitors, and signal pathway regulators (Lim et al., 2022). Its format and curation support systematic identification of new therapeutic targets across diverse disease models. It is widely referenced for applications in cancer and neurodegenerative disease research.

Biological Rationale

Drug libraries containing only FDA- or globally approved compounds offer unique translational value. Each compound in the DiscoveryProbe™ FDA-approved Drug Library has confirmed clinical safety and efficacy in at least one major regulatory jurisdiction, including the FDA, EMA, HMA, CFDA, or PMDA (ApexBio). This allows high-throughput screening (HTS) and high-content screening (HCS) campaigns to focus on molecules with known human pharmacokinetics, toxicity profiles, and established bioactivity. In oncology, for example, repositioning efforts leverage this library to rapidly identify synergistic combinations, as illustrated by combination screens in hepatocellular carcinoma (HCC) patient-derived models (Lim et al., 2022). Similar approaches are applied in neurodegenerative disease models and enzyme inhibitor research, maximizing translational potential while minimizing early-stage attrition. The inclusion of diverse mechanistic classes (receptor modulators, enzyme inhibitors, ion channel regulators) further expands the scope for phenotypic screening and pathway deconvolution.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library contains compounds representing multiple mechanistic classes:

• Receptor agonists and antagonists: Targeting GPCRs, nuclear hormone receptors, and growth factor receptors. Example: doxorubicin as a topoisomerase II inhibitor and cytotoxic agent.
• Enzyme inhibitors: Including kinase inhibitors (e.g., sorafenib, approved for HCC), proteasome inhibitors (bortezomib, ixazomib), and metabolic pathway modulators (metformin, an AMPK activator).
• Ion channel modulators: Agents such as calcium channel blockers, antiarrhythmics, and anticonvulsants.
• Signal pathway regulators: Small molecules that modulate pathways like JNK, MAPK, PI3K/AKT, and others, which are frequently implicated in cancer, metabolic, and neurological disorders (Lim et al., 2022).

This mechanistic diversity enables precise mapping of compound effects to cellular pathways and identification of new therapeutic targets. Many drugs in the library have been structurally characterized, facilitating structure-activity relationship (SAR) analyses and integration with computational docking or virtual screening workflows (see analysis). This article extends prior work by summarizing how these mechanistic classes are leveraged in systematic HTS applications beyond traditional oncology screening.

Evidence & Benchmarks

• High-throughput screens using the DiscoveryProbe™ FDA-approved Drug Library identified proteasome and CDK inhibitors as effective combinations against HCC in patient-derived xenografts (Lim et al., 2022, https://doi.org/10.1186/s13046-022-02436-9).
• Compounds provided in 10 mM DMSO solutions are stable for 12 months at -20°C, and 24 months at -80°C, enabling long-term screening campaigns (ApexBio).
• Representative drugs include doxorubicin (cytotoxic, topoisomerase II inhibitor), metformin (AMPK activator), and atorvastatin (HMG-CoA reductase inhibitor), each with well-validated clinical and mechanistic profiles (ApexBio).
• Integration with phenotypic and mechanistic screening enables rapid target identification in cancer and neurodegenerative disease models (contrasted here—this article details structural integration workflows).
• Validated use in enzyme inhibitor screens and precision medicine applications in rare disease contexts (see enzyme screening focus—here, broader mechanistic coverage is emphasized).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is primarily used for:

• Drug repositioning screens: Leveraging approved drugs for novel indications based on phenotypic or mechanistic assays.
• Pharmacological target identification: Mapping of drug effects to cellular pathways and biomarkers.
• Cancer research: Systematic identification of effective drug combinations in patient-derived models.
• Neurodegenerative disease studies: Screening for modulators of protein aggregation, neuroprotection, or synaptic signaling.
• Enzyme inhibitor screening: Rapid assessment of inhibitory profiles for kinases, proteases, and metabolic enzymes.

Common Pitfalls or Misconceptions

• Not all compounds are globally approved: Some are approved in select regions or listed in pharmacopeias, not universally.
• In vitro hit does not guarantee in vivo efficacy: Clinical context and pharmacodynamics must be considered.
• Mechanistic annotations may not capture off-target effects: Some compounds act via multiple pathways.
• Screening concentrations may not reflect clinical dosing: 10 mM stock allows a wide range, but optimal screening concentrations should be titrated.
• Not suitable for primary toxicology assessment: All compounds have established safety, but new combinations require additional validation.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is provided as pre-dissolved 10 mM solutions in DMSO. Formats include 96-well microplates, deep well plates, and 2D barcoded screw-top storage tubes. The library is compatible with robotic liquid handling systems and automated high-throughput screening platforms. Sample shipping is performed on blue ice for evaluation sizes, and at room temperature or blue ice upon request for other volumes. For HTS/HCS workflows, compounds are typically diluted to final assay concentrations ranging from 1–50 µM, depending on target class and cell model requirements. Storage at -20°C (12 months) or -80°C (24 months) is recommended to maintain compound integrity (ApexBio).

Researchers investigating signaling pathways, disease models, or pharmacological mechanisms can integrate this resource into established screening protocols. For guidance on strategic mechanistic screening and translational workflows, see this strategic perspective—this article provides updated evidence benchmarks and workflow parameters.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a validated, flexible resource for drug repositioning, pharmacological target identification, and mechanistic screening. Its curated, clinically approved compound set supports rapid translation from bench to bedside, particularly in oncology, neurodegeneration, and enzyme inhibitor research. By enabling systematic discovery of novel drug activities and synergies, it accelerates therapeutic innovation and de-risks early-stage development. For detailed compound lists, storage/handling protocols, and ordering, visit the product page.